LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of April 19, 2024, LLY stock price declined to $726.31 with 3,151,791 million shares trading.

LLY has a beta of 0.29, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.01 to the broad based SPY ETF.

LLY has a market cap of $689.47 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $9 billion in Revenue and $2.49 earnings per share. This beat revenue expectation by $423 million and exceeded earnings estimates by $.30.

In the last 3 years, LLY stock traded as high as $800.78 and as low as $178.58.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, SPY, VUG, IVV.

LLY has outperformed the market in the last year with a return of +97.6%, while the SPY ETF gained +21.2%. In the last 3 month period, LLY beat the market returning +16.7%, while SPY returned +4.3%. However, in the most recent 2 weeks LLY has underperformed the stock market by returning -5.4%, while SPY returned -3.5%.

LLY support price is $734.34 and resistance is $757.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY stock will trade within this expected range on the day.